Pictet Asset Management (UK)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Pictet Asset Management (UK)’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$79.3M	Sell	123,071 -49,789	-29%	-$30.3M	0.09%	263
2021 Q1	$98.7M	Buy	172,860 +6,783	+4%	+$4.02M	0.12%	212
2020 Q4	$96.8M	Sell	166,077 -43,165	-21%	-$24.6M	0.13%	203
2020 Q3	$108M	Buy	209,242 +14,335	+7%	+$7.26M	0.17%	166
2020 Q2	$88M	Sell	194,907 -30,763	-14%	-$13.6M	0.15%	178
2020 Q1	$79.1M	Buy	225,670 +42,904	+23%	+$15.8M	0.17%	160
2019 Q4	$67.6M	Buy	182,766 +108,320	+146%	+$38.2M	0.12%	217
2019 Q3	$24.8M	Hold	74,446	–	–	0.05%	356
2019 Q2	$23.3M	Sell	74,446 -8,838	-11%	-$2.65M	0.05%	358
2019 Q1	$25.5M	Buy	83,284 +39,398	+90%	+$10.6M	0.06%	348
2018 Q4	$10.2M	Buy	43,886 +6,214	+16%	+$1.67M	0.03%	497
2018 Q3	$11.8M	Buy	+37,672	New	+$11.7M	0.02%	525

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management (UK)'s BIO Position: Q2 2021 in Review

Pictet Asset Management (UK) reduced its Bio-Rad Laboratories Class A (BIO) stake by 29% in Q2 2021, selling an estimated $30.3M and leaving 123,071 shares worth $79.3M. The position accounts for 0.09% of the portfolio, ranked #263.

Pictet Asset Management (UK) first reported a position in BIO in Q3 2018 and has held it in 12 quarters since. The position peaked at $108M in Q3 2020. 509 funds tracked by Wall St. Rank hold BIO as of Q2 2021.

Pictet Asset Management (UK) held 123,071 shares of Bio-Rad Laboratories Class A worth $79.3M as of Q2 2021.
Pictet Asset Management (UK) sold 49,789 Bio-Rad Laboratories Class A shares in Q2 2021, an estimated $30.3M.
Bio-Rad Laboratories Class A made up 0.09% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #263 holding.
Pictet Asset Management (UK) first reported a position in Bio-Rad Laboratories Class A in Q3 2018 and has held it in 12 quarters since.
Pictet Asset Management (UK)'s Bio-Rad Laboratories Class A position peaked at $108M in Q3 2020.
509 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.